Compare AbCellera Biologics Inc (ABCL) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Boston Beer Company Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Boston Beer Company Inc trades at $179.02 (market cap $1.91B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | SAM | |
|---|---|---|
Market Cap | $2.35B | $1.91B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $260.05 |
52-Week Low | $2.78 | $161.08 |
Enterprise Value | $1.99B | $1.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Boston Beer (SAM) trades at $183.16, down 0.25% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but negative net income margin of -3.15% and ROE of -7.75%. Recent Q1 2026 earnings missed expectations, though Q3 and Q4 2025 beat estimates. Cash flow improved to $11.56M net in 2025 after a negative 2024. Analyst consensus price target is $233.40 with 74% hold ratings.
SAM faces headwinds from declining volume growth and brand pressure, but maintains strong gross margins at 48.7%. The 27% upside to consensus target offers potential, though execution risks and competitive beverage market pose challenges. Institutional sentiment is cautious with limited buy ratings despite positive cash flow recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
